Metabolomics Analysis Identifies Differential Metabolites as Biomarkers for Acute Myocardial Infarction

Author:

Zhou Jie12,Hou Hai-Tao123,Song Yu24,Zhou Xiao-Lin24,Chen Huan-Xin123,Zhang Li-Li123,Xue Hong-Mei123,Yang Qin123,He Guo-Wei123ORCID

Affiliation:

1. Department of Cardiac Surgery & The Institute of Cardiovascular Diseases, TEDA International Cardiovascular Hospital, Tianjin University, Tianjin 300457, China

2. Tianjin Key Laboratory of Molecular Regulation of Cardiovascular Diseases and Translational Medicine, Tianjin 300457, China

3. Department of Cardiac Surgery & The Institute of Cardiovascular Diseases, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences, Tianjin 300457, China

4. Department of Cardiology & The Institute of Cardiovascular Diseases and the Critical Care Unit, TEDA International Cardiovascular Hospital, Tianjin University, Chinese Academy of Medical Sciences, Tianjin 300457, China

Abstract

Myocardial infarction (MI), including ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI), is still a leading cause of death worldwide. Metabolomics technology was used to explore differential metabolites (DMs) as potential biomarkers for early diagnosis of STEMI and NSTEMI. In the study, 2531 metabolites, including 1925 DMs, were discovered. In the selected 27 DMs, 14 were successfully verified in a new cohort, and the AUC values were all above 0.8. There were 10 in STEMI group, namely L-aspartic acid, L-acetylcarnitine, acetylglycine, decanoylcarnitine, hydroxyphenyllactic acid, ferulic acid, itaconic acid, lauroylcarnitine, myristoylcarnitine, and cis-4-hydroxy-D-proline, and 5 in NSTEMI group, namely L-aspartic acid, arachidonic acid, palmitoleic acid, D-aspartic acid, and palmitelaidic acid. These 14 DMs may be developed as biomarkers for the early diagnosis of MI with high sensitivity and specificity. These findings have particularly important clinical significance for NSTEMI patients because these patients have no typical ECG changes.

Funder

National Natural Science Foundation of China

Tianjin Municipal Science and Technology Bureau

Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences

Tianjin Municipal Heath Commission

TEDA International Cardiovascular Hospital

Tianjin Key Medical Discipline (Specialty) Construction Project

Publisher

MDPI AG

Reference36 articles.

1. Diagnosis and treatment of acute coronary syndromes: A review;Bhatt;JAMA,2022

2. American Heart Association (2023, April 28). Focus on Quality. Available online: http://www.heart.org/en/professional/quality-improvement.

3. Acute myocardial infarction;Boateng;Disease-a-Month,2013

4. Heart disease and stroke statistics-2023 update: A report from the American Heart Association;Tsao;Circulation,2023

5. Surendran, A., Atefi, N., Zhang, H., Aliani, M., and Ravandi, A. (2021). Defining acute coronary syndrome through metabolomics. Metabolites, 11.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3